XBiotech Inc. — Q1 2024 Form 10-Q
Business context and period. XBiotech is a pre-revenue biopharmaceutical company developing naturally occurring “True Human” antibody therapies. Its pipeline includes IL-1α-targeting candidates in oncology, rheumatology and neurology. This unaudited report covers the three months ended March 31, 2024, compared with Q1 2023; balance-sheet figures are compared with December 31, 2023. Unless stated otherwise, amounts below are in U.S. dollars.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $9.825 million | $6.230 million |
| General and administrative expense | $1.028 million | $0.915 million |
| Total operating expenses / operating loss | $10.853 million | $7.145 million |
| Net loss | $10.002 million | $3.816 million |
| Net loss per share, basic and diluted | $0.33 | $0.13 |
| Operating cash used | $7.202 million | $4.808 million |
| Cash and cash equivalents | $201.039 million | $200.023 million at Dec. 31, 2023 |
| Total assets | $227.858 million | $226.615 million at Dec. 31, 2023 |
| Total liabilities | $18.578 million | $7.769 million at Dec. 31, 2023 |
No revenue was reported, so revenue growth and operating margins are not meaningful. Net loss increased about 162% year over year. R&D expense rose 58%, mainly due to increased clinical-trial activity and higher salaries and related expenses; G&A increased 12%. Interest income was $2.658 million, while a $1.582 million foreign-exchange loss reduced other income. The financial statements report total other income of $876,000 for Q1 2024 and $3.292 million for Q1 2023.
Cash used in investing activities was $255,000, primarily associated with preparation for a new facility. Financing activities provided $10.055 million, including the $10 million related-party loan and $55,000 from stock-option exercises. The quarter-end cash balance increased by $1.016 million from year-end, after the reported foreign-exchange effect.
Material changes and financing
- On January 3, 2024, XBiotech received a $10 million convertible loan from founder, CEO and Chairman John Simard to fund construction of a new Austin research and development facility. The loan is secured by company real estate and cash, bears 8% simple annual interest, and has a $4.048 per-share conversion price, subject to a 19.9% ownership cap.
- The lender may elect repayment or conversion under specified conditions, including certain defaults and, under acceleration provisions, a share price below $3 or company cash below $65 million. The loan also permits repayment at the lender’s election one year after funding, subject to the agreement’s terms.
- Share-based compensation was $381,000, versus $705,000 in Q1 2023. The company issued 13,917 shares through option exercises and reported 30,450,881 shares outstanding at March 31, 2024.
Outlook, risks and other disclosures
- Management expects no revenue during the next year and expects significant, increasing operating losses as candidates advance through development. It says the $201.0 million cash balance is expected to fund operations for at least 12 months from the filing date and to support several potential clinical-program milestones.
- The company cautions that clinical development costs may increase and that it cannot allocate internal R&D costs precisely by candidate. Profitability depends on future revenue, which may not occur; product revenue would require regulatory approval and successful commercialization.
- Key risks include clinical-trial execution and outcomes, regulatory approval, recruiting patients and employees, commercialization, intellectual-property protection, competition, and the need for future financing. The company reported no material changes to the risk factors in its 2023 Form 10-K.
- Management concluded disclosure controls and procedures were effective. The filing reports no material change in internal control over financial reporting. No off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Assess whether the stated cash runway and expected clinical milestones remain achievable against the company’s operating-loss and R&D spending trajectory.
- Review the related-party loan agreement, including its collateral, interest, conversion terms, repayment rights and acceleration triggers.
- Check the reported financial statements against the MD&A: its other-income table appears inconsistent with the statements (including the Q1 2023 sign), and its cash-flow discussion labels the periods as 2023 and 2022 although the financial statements compare Q1 2024 and Q1 2023.
- Track clinical progress, regulatory and trial costs, foreign-exchange exposure, and any need for additional financing; the filing gives no quantified revenue or profitability guidance.